Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

被引:26
作者
Dano, Helene [1 ]
Altinay, Serdar [2 ]
Arnould, Laurent [3 ]
Bletard, Noella [4 ]
Colpaert, Cecile [5 ]
Dedeurwaerdere, Franceska [6 ]
Dessauvagie, Benjamin [7 ]
Duwel, Valerie [8 ]
Floris, Giuseppe [9 ,10 ]
Fox, Stephen [11 ,12 ]
Gerosa, Clara [13 ]
Jaffer, Shabnam [14 ,15 ]
Kurpershoek, Eline [16 ]
Lacroix-Triki, Magali [17 ]
Laka, Andoni [18 ]
Lambein, Kathleen [19 ]
MacGrogan, Gaetan Marie [20 ]
Marchio, Caterina [21 ,22 ]
Martinez, Dolores Martin [23 ]
Nofech-Mozes, Sharon [24 ]
Peeters, Dieter [25 ,26 ]
Ravarino, Alberto [13 ]
Reisenbichler, Emily [27 ]
Resetkova, Erika [28 ]
Sanati, Souzan [29 ]
Schelfhout, Anne-Marie [30 ]
Schelfhout, Vera [25 ]
Shaaban, Abeer M. [31 ]
Sinke, Renata [16 ]
Stanciu-Pop, Claudia Maria [32 ]
Stobbe, Claudia [16 ]
van Deurzen, Carolien H. M. [33 ]
Van de Vijver, Koen [34 ]
Van Rompuy, Anne-Sophie [9 ]
Verschuere, Stephanie [6 ]
Vincent-Salomon, Anne [35 ]
Wen, Hannah [36 ]
Bouzin, Caroline [37 ]
Galant, Christine [1 ,38 ]
Van Bockstal, Mieke R. [1 ,38 ]
机构
[1] Clin Univ St Luc Bruxelles, Dept Pathol, Ave Hippocrate 10, B-1200 Woluwe St Lambert, Belgium
[2] Univ Hlth Sci, Dept Pathol, Bakirkoy Dr Sadi Konuk Hlth Applicat & Res Ctr, TR-34147 Istanbul, Turkey
[3] Ctr George Francois Leclerc, Dept Biol & Pathol Tumeurs, 1 Rue Pr Marion, F-21000 Dijon, France
[4] CHU Liege, Dept Pathol, Site Sart Tilman,Ave Hop 1, B-4000 Liege, Belgium
[5] GZA ZNA Hosp, Dept Pathol, B-2610 Antwerp, Belgium
[6] AZ Delta, Dept Pathol, Westlaan 123, B-8800 Roeselare, Belgium
[7] Univ Western Australia, Med Sch, Div Pathol & Lab Med, Crawley, WA 6009, Australia
[8] AZ Klina Brasschaat, Dept Pathol, Augustijnslei 100, B-2930 Brasschaat, Belgium
[9] KU Leuven Univ Leuven, Univ Hosp Leuven, Dept Pathol, Herestr 49, B-3000 Leuven, Belgium
[10] KU Leuven Univ Leuven, Dept Imaging & Pathol, Lab Translat Cell & Tissue Res, Leuven, Belgium
[11] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic 3000, Australia
[12] Univ Melbourne, Melbourne, Vic 3000, Australia
[13] Univ Cagliari, Dept Pathol, AOU San Giovanni di Dio, Via Osped 54, I-09124 Cagliari, Italy
[14] Mt Sinai Hosp, Dept Pathol, New York, NY 10029 USA
[15] Icahn Sch Med, New York, NY 10029 USA
[16] Pathan BV, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands
[17] Gustave Roussy, Dept Pathol, Canc Campus,114 Rue Edouard Vaillant, F-94805 Villejuif, France
[18] CNDG, Dept Pathol, Chaussee de Nivelles 212, B-6041 Gosselies, Belgium
[19] St Lucas Hosp, Dept Pathol, Groenebriel 1, B-9000 Ghent, Belgium
[20] Inst Bergonie, Dept Pathobiol, Surg Pathol Unit, F-33076 Bordeaux, France
[21] Univ Turin, Dept Med Sci, I-10126 Turin, Italy
[22] IRCCS, Pathol Unit, Candiolo Canc Inst, FPO, Candiolo, Italy
[23] Curepath, Rue Borfilet 12A, B-6040 Jumet, Belgium
[24] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON M4N 3M5, Canada
[25] AZ St Maarten, Dept Pathol, Liersesteenweg 435, B-2800 Mechelen, Belgium
[26] HistoGeneX, Histopathol Imaging & Quantificat Unit, Sint Bavostr 78, B-2610 Antwerp, Belgium
[27] Yale New Haven Hosp, Dept Pathol, Yale Sch Med, 310 Cedar St, New Haven, CT 06510 USA
[28] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[29] Washington Univ, Dept Pathol & Immunol, Sch Med, 660S Euclid Blvd, St Louis, MO 63110 USA
[30] Onze Lieve Vrouwziekenhuis Aalst, Dept Pathol, Moorselbaan 164, B-9300 Aalst, Belgium
[31] Univ Birmingham, Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Birmingham B15 2GW, W Midlands, England
[32] CHU UCL Namur, Dept Pathol, Ave Docteur G Therasse 1,Site Godinne, B-5530 Yvoir, Belgium
[33] Erasmus MC, Dept Pathol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[34] Ghent Univ Hosp, Dept Pathol, C Heymanslaan 10, B-9000 Ghent, Belgium
[35] Inst Curie, INSERM U934, Pole Med Diagnost & Theranost, 26 Rue Ulm, F-75248 Paris 05, France
[36] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA
[37] Catholic Univ Louvain, Inst Clin & Expt Res IREC, 2IP IREC Imaging Platform, Ave Hippocrate 55, B-1200 Brussels, Belgium
[38] Catholic Univ Louvain, Inst Clin & Expt Res IREC, Ave Hippocrate 55, B-1200 Brussels, Belgium
关键词
LOCAL RECURRENCE; REPRODUCIBILITY; CLASSIFICATION; PATHOLOGISTS; RELIABILITY; CANCER; GRADE; RISK; CONSISTENCY; DIAGNOSIS;
D O I
10.1038/s41379-019-0367-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histopathological assessment of ductal carcinoma in situ, a nonobligate precursor of invasive breast cancer, is characterized by considerable interobserver variability. Previously, post hoc dichotomization of multicategorical variables was used to determine the "ideal" cutoffs for dichotomous assessment. The present international multicenter study evaluated interobserver variability among 39 pathologists who performed upfront dichotomous evaluation of 149 consecutive ductal carcinomas in situ. All pathologists independently assessed nuclear atypia, necrosis, solid ductal carcinoma in situ architecture, calcifications, stromal architecture, and lobular cancerization in one digital slide per lesion. Stromal inflammation was assessed semiquantitatively. Tumor-infiltrating lymphocytes were quantified as percentages and dichotomously assessed with a cutoff at 50%. Krippendorff's alpha (KA), Cohen's kappa and intraclass correlation coefficient were calculated for the appropriate variables. Lobular cancerization (KA = 0.396), nuclear atypia (KA = 0.422), and stromal architecture (KA = 0.450) showed the highest interobserver variability. Stromal inflammation (KA = 0.564), dichotomously assessed tumor-infiltrating lymphocytes (KA = 0.520), and comedonecrosis (KA = 0.539) showed slightly lower interobserver disagreement. Solid ductal carcinoma in situ architecture (KA = 0.602) and calcifications (KA = 0.676) presented with the lowest interobserver variability. Semiquantitative assessment of stromal inflammation resulted in a slightly higher interobserver concordance than upfront dichotomous tumor-infiltrating lymphocytes assessment (KA = 0.564 versus KA = 0.520). High stromal inflammation corresponded best with dichotomously assessed tumor-infiltrating lymphocytes when the cutoff was set at 10% (kappa = 0.881). Nevertheless, a post hoc tumor-infiltrating lymphocytes cutoff set at 20% resulted in the highest interobserver agreement (KA = 0.669). Despite upfront dichotomous evaluation, the interobserver variability remains considerable and is at most acceptable, although it varies among the different histopathological features. Future studies should investigate its impact on ductal carcinoma in situ prognostication. Forthcoming machine learning algorithms may be useful to tackle this substantial diagnostic challenge.
引用
收藏
页码:354 / 366
页数:13
相关论文
共 54 条
[1]  
[Anonymous], J NATL CANCER INST M
[2]   Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast [J].
Bethwaite, P ;
Smith, N ;
Delahunt, B ;
Kenwright, D .
JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (06) :450-454
[3]   The Advantage of Discordance: An Example Using the Highly Subjective Nuclear Grading of Breast Cancer [J].
Dalton, Leslie W. ;
Gerds, Thomas A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (08) :1105-1111
[4]   The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology [J].
Darragh, Teresa M. ;
Colgan, Terence J. ;
Cox, J. Thomas ;
Heller, Debra S. ;
Henry, Michael R. ;
Luff, Ronald D. ;
McCalmont, Timothy ;
Nayar, Ritu ;
Palefsky, Joel M. ;
Stoler, Mark H. ;
Wilkinson, Edward J. ;
Zaino, Richard J. ;
Wilbur, David C. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2013, 32 (01) :76-115
[5]   Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer [J].
Dieci, Maria Vittoria ;
Radosevic-Robin, Nina ;
Fineberg, Susan ;
van den Eynden, Gert ;
Ternes, Nils ;
Penault-Llorca, Frederique ;
Pruneri, Giancarlo ;
D'Alfonso, Timothy M. ;
Demaria, Sandra ;
Castaneda, Carlos ;
Sanchez, Joselyn ;
Badve, Sunil ;
Michiels, Stefan ;
Bossuyt, Veerle ;
Rojo, Federico ;
Singh, Baljit ;
Nielsen, Torsten ;
Viale, Giuseppe ;
Kim, Seong-Rim ;
Hewitt, Stephen ;
Wienert, Stephan ;
Loibl, Sybille ;
Rimm, David ;
Symmans, Fraser ;
Denkert, Carsten ;
Adams, Sylvia ;
Loi, Sherene ;
Salgado, Roberto .
SEMINARS IN CANCER BIOLOGY, 2018, 52 :16-25
[6]   Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial [J].
Donker, Mila ;
Litiere, Saskia ;
Werutsky, Gustavo ;
Julien, Jean-Pierre ;
Fentiman, Ian S. ;
Agresti, Roberto ;
Rouanet, Philippe ;
de lara, Christine Tunon ;
Bartelink, Harry ;
Duez, Nicole ;
Rutgers, Emiel J. T. ;
Bijker, Nina .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4054-4059
[7]   Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast [J].
Douglas-Jones, AG ;
Morgan, JM ;
Appleton, MAC ;
Attanoos, RL ;
Caslin, A ;
Champ, CS ;
Cotter, M ;
Dallimore, NS ;
Dawson, A ;
Fortt, RW ;
Griffiths, AP ;
Hughes, M ;
Kitching, PA ;
O'Brien, C ;
Rashid, AM ;
Stock, D ;
Verghese, A ;
Williams, DW ;
Williams, NW ;
Williams, S .
JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (08) :596-602
[8]  
Elmore JG, 2015, JAMA-J AM MED ASSOC, V313, P1122, DOI 10.1001/jama.2015.1405
[9]   PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].
ELSTON, CW ;
ELLIS, IO .
HISTOPATHOLOGY, 1991, 19 (05) :403-410
[10]   Trends in Breast Cancer Mortality by Stage at Diagnosis Among Young Women in the United States [J].
Guo, Fangjian ;
Kuo, Yong-fang ;
Shih, Ya Chen Tina ;
Giordano, Sharon H. ;
Berenson, Abbey B. .
CANCER, 2018, 124 (17) :3500-3509